Sintilimab alone for early-stage MSI-H/dMMR endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a single drug, sintilimab, for people with early-stage (I–II) endometrial cancer that has a specific genetic feature (MSI-H or dMMR). The goal is to see if this treatment can shrink or control the cancer while allowing people to avoid or delay standard surgery, especially for those who want to preserve fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have endometrial cancer that is stage I or II (early stage) and has a specific genetic marker called MSI-H or dMMR.
- You must want to avoid surgery to preserve fertility, or you cannot have standard surgery because of other health issues.
- You must have at least one tumor that can be measured on scans.
- You must be in good general health (able to carry out daily activities, ECOG 0-1).
- You must not have active autoimmune disease, severe infections, or have had prior immune checkpoint inhibitor treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
This trial tests a combination of two drugs – fruquintinib (a pill that targets blood vessels feeding tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer) – for people with advanced endometrial cancer that has already been treated with platinum chemotherapy. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
This trial tests whether an immunotherapy combination can help shrink or control endometrial cancer so that surgery might not be needed. It is for people whose tumors have a specific genetic feature (dMMR/MSI-H) that may respond well to this treatment.
This trial tests a combination of two drugs, sintilimab (an immunotherapy that helps the immune system fight cancer) and gossypol acetate (a drug that may make cancer cells more vulnerable), for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can slow or stop the cancer.
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Hear when a new MMRd Endometrial Cancer of Stage I~II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.